2-(4-sulfo-butyl)-2,3,4,9-tetrahydro-1 H-b-carboline-6-carboxylic acid methyl ester | 393175-78-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-(4-sulfo-butyl)-2,3,4,9-tetrahydro-1 H-b-carboline-6-carboxylic acid methyl ester
• 英文别名: 4-(6-Methoxycarbonyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl)butane-1-sulfonic acid
• CAS: 393175-78-5
• 化学式: C₁₇H₂₂N₂O₅S
• 分子量: 366.438
• InChiKey: WJBZYQPIKNAUON-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  108
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Amyloid targeting imaging agents and uses thereof
  申请人：——

  公开号：US20020115717A1

  公开（公告）日：2002-08-22

  Amyloid-targeting imaging agents such as radiolabeled amyloid targeting molecules and amyloid targeting molecule-chelator conjugates for imaging, e.g., amyloid plaques in vivo, and/or for the treatment of amyloidosis disorders. The invention provides amyloid-targeting imaging agents that are useful for imaging sites of amyloid disease. Imaging agents of the invention are capable of binding specifically to amyloid plaques, as an aid in diagnosis and/or early treatment of amyloidosis disorders.

  淀粉样蛋白靶向成像剂，如放射性标记的淀粉样蛋白靶向分子和淀粉样蛋白靶向分子-螯合剂共轭物，用于例如体内淀粉样蛋白斑块的成像，和/或用于淀粉样变性疾病的治疗。本发明提供的淀粉样蛋白靶向成像剂可用于淀粉样蛋白疾病部位的成像。本发明的成像剂能够与淀粉样蛋白斑块特异性结合，有助于淀粉样变性疾病的诊断和/或早期治疗。
• AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF
  申请人：Neurochem, Inc.

  公开号：EP1303311A2

  公开（公告）日：2003-04-23
• US7311893B2
  申请人：——

  公开号：US7311893B2

  公开（公告）日：2007-12-25
• [EN] AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF<br/>[FR] AGENTS D'IMAGERIE CIBLANT LES SUBSTANCES AMYLOIDES ET UTILISATION DESDITS AGENTS
  申请人：NEUROCHEM INC

  公开号：WO2002007781A2

  公开（公告）日：2002-01-31

  Amyloid-targeting imaging agents such as radiolabeled amyloid targeting molecules and amyloid targeting molecule-chelator conjugates for imaging, e.g., amyloid plaques in vivo, and/or for the treatment of amyloidosis disorders. The invention provides amyloid-targeting imaging agents that are useful for imaging sites of amyloid disease. Imaging agents of the invention are capable of binding specifically to amyloid plaques, as an aid in diagnosis and/or early treatment of amyloidosis disorders.